Edition:
United States

People: G1 Therapeutics Inc (GTHX.OQ)

GTHX.OQ on NASDAQ Stock Exchange Global Select Market

37.23USD
16 Aug 2019
Change (% chg)

$-0.17 (-0.45%)
Prev Close
$37.40
Open
$38.21
Day's High
$38.21
Day's Low
$35.34
Volume
123,955
Avg. Vol
153,505
52-wk High
$69.23
52-wk Low
$13.92

Eshelman, Fredric 

Dr. Fredric N. Eshelman Pharm.D. is an Independent Director of G1 Therapeutics Inc. Dr. Eshelman has served as a member of our Board of Directors since February 2015. Dr. Eshelman founded Eshelman Ventures, LLC in March 2014, which invests in a variety of companies, primarily in the healthcare sector, and has served as a principal since its founding. Dr. Eshelman served as Chief Executive Officer for Pharmaceutical Product Development, Inc., a contract research organization, from June 1990 to December 2011, as Senior Vice President, Development and a member of the board of directors of the former Glaxo Inc., a pharmaceutical company, from 1989 to 1990. Since September 2015, Dr. Eshelman has served as the chairman of the board of directors of The Medicines Company, a publicly traded biopharmaceutical company. Dr. Eshelman also currently serves as chairman of the board of directors of Eyenovia, Inc., a publicly traded biopharmaceutical company, where he has been a member of the board of directors since December 2014, and he has served on the board of directors of Valeant Pharmaceuticals International, Inc., a publicly traded Canadian pharmaceutical company, since March 2016. Dr. Eshelman previously served on the board of directors of Furiex Pharmaceuticals, a publicly traded biopharmaceutical company, from 2010 until July 2014, when it was sold to Forest Labs/Actavis, and of Pharmaceutical Product Development, Inc., a contract research organization that was publicly traded until 2011, from 1986 until 2011. He also serves on the boards of directors of a number of privately held biopharmaceutical companies. Dr. Eshelman also served on the executive committee of the Medical Foundation of North Carolina, the board of the North Carolina Biotechnology Center, and the Board of Trustees for the University of North Carolina at Wilmington. In addition, Dr. Eshelman serves as an adjunct professor at the University of North Carolina at Chapel Hill School of Pharmacy, where he chairs the Board of Visitors.

Basic Compensation

Total Annual Compensation, USD 304,973
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 304,973

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Garry Nicholson

922,808

Mark Velleca

1,914,650

Barclay Phillips

714,880

Terry Murdock

2,748,750

Rajesh Malik

688,715

Jay Strum

--
As Of  30 Dec 2018